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INTRODUCTION: The goal of antihypertensive treatment is to reduce blood pressure without interfering in health-related quality 
of life (HRQL) 
OBJECTIVE: This study aimed to assess the influence of hypertension control upon HRQL in hypertensive patients with and 
without complications. 
MATERIALS AND METHODS: Seventy-seven hypertensive outpatients (71% women, 58% white, 60% with elementary school 
level education, average age 54 ± 8 years) were observed during a 12-month special care program (phase 1: clinical visits every 
two months, donation of all antihypertensive medications, meetings with a multidisciplinary team, and active telephone calls) and 
three years of standard care (phase 2: clinical visits every four months, medication provided by the drugstore of the hospital with a 
two-hour wait and a possible lack of medication, no meetings with a multidisciplinary team or active telephone calls). The patient 
HRQL was assessed using Bulpitt and Fletcher’s Specific Questionnaire, as well as the SF-36 scores. Hypertensive patients were 
divided into “with complications” (n=37, diastolic blood pressure great than 110 mm Hg for patients with or without treatment, 
with clinically evident target-organ or other associated illness) and “without complications” (n=40). The variables studied were 
quality of life, blood pressure control, hypertension gravity, and demographic characteristics. 
RESULTS: In hypertensive patients with and without complications, both the systolic and diastolic blood pressure were significantly 
higher (p<0.05) in phase 2 of observation (143±18/ 84±11 and 144±21/93±11 mm Hg for patients with and without complications 
, respectively) relative to phase 1 (128±17/ 75±13 and 128±15/ 83±11mmHg). The proportion of patients with controlled blood 
pressure (defined as a blood pressure less than 140/90 mm Hg) decreased from 70% to 49% in the “with complications” group and 
from 78% to 50% in the “without complications” group during phase 2 of observation. The patients with complications showed 
a decrease in bodily pain, vitality, and mental health component summary scores in both phases. In phase 2, the patients with-
out complications had significantly better HRQL scores compared to complicated patients using both the Bulpitt and Fletcher’s 
Questionnaire and the SF-36 assessment of physical capacity, bodily pain, and vitality domain summary scores. With regards to 
hypertension control, there was a significant decrease from phase 1 to phase 2 in the vitality component summary scores and an 
increase in the emotional aspect component summary scores assessed by the SF-36, whereas Bulpitt and Fletcher’s Questionnaire 
showed no differences in these scores. 
CONCLUSION: Special care programs with multidisciplinary activities, individualized and personalized assistance, easy access 
to pharmacological treatment, frequent meetings, and active telephone calls for hypertensive patients significantly increase blood 
pressure control but do not interfere with the HRQL.
KEYWORDS: Health-related quality of life; Hypertension; Blood pressure control; Treatment; Educational.
INTRODUCTION
Hypertension is a highly prevalent disease. In most 
countries, 15% to 30% of the adult population and more 
than 50% of the elderly population suffer from high blood 
pressure, making it a clear general public health problem. As 620
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with smoking, diabetes, and dyslipidemia, hypertension is an 
important risk factor for cardiovascular diseases, which are 
responsible for roughly 30% of deaths worldwide,1-6
There is evidence that antihypertensive treatment 
significantly decreases cardiovascular morbidity and 
mortality.7,8 Despite this evidence, it has been observed 
that the proportion of hypertensive patients in which blood 
pressure is adequately controlled is relatively low.. In the 
United States, data from the National Health and Nutrition 
Examination Survey (NHANES) showed that 70% of 
hypertensive patients were aware of having the disease, 59% 
were under treatment, but only 34% had their hypertension 
under control.9 Studies carried out in other countries 
revealed a similar low rate of blood pressure control: 25% 
in Belgium,10 21% in the Czech Republic,11 13.6% in India,12 
15% in Hungary,13 10% in Áustria,13 38% in England,14 
8% in Egypt,13 5% in Slovakia,14 less than 5% in China,15 
and 2.2% in Northern Greece.16 Brazil is no exception, as 
multiple studies have demonstrated that approximately 
30% of Brazilian hypertensive patients have adequate blood 
pressure control.17,18 For example, Strelec et al. studied 130 
hypertensive patients and found that only 35% of this cohort 
had good blood pressure control.19
An important aspect in the treatment of hypertension 
that must be considered is that treatment should not 
interfere with patient’s quality of life.20 Adverse effects from 
treatment drugs, diseases associated with hypertension, and 
simply being diagnosed with the disease since it is related 
to increased mortality can all decrease patient quality of 
life.21 As such, the interest in assessing the health-related 
quality of life (HRQL) has increased significantly in the 
past few decades. One example of this interest is the Dietary 
Approaches to Stop Hypertension Trial (DASH), which has 
analyzed how effective three diets were for lowering blood 
pressure and preserving the HRQL. The DASH Diet (rich in 
fruits, vegetables, and low-fat dairy products and reduced in 
saturated and total fat) decreased blood pressure significantly 
and increased the HRQL as assessed by the Medical 
Outcomes Study Short Form-36 (SF-36) questionnaire in 
all groups studied.22 In studies such as TOHP (Trials of 
Hypertension Prevention)23 and TOMHS (Treatment of Mild 
Hypertension),24 the decreased in blood pressure decrease 
was followed by an improvement in the HRQL.
The domains of HRQL chosen for evaluation in most 
studies involving hypertension are those that reflect 
the potential adverse effects of the treatment on work 
performance, sexual function, and humor.25 Aydemir et 
al.26 showed that hypertensive patients have a statistically 
significant decrease in all HRQL domains as assessed by the 
SF-36 when compared to normotensive patients. This study 
also showed that hypertensive patients with target-organ 
damage are those with the lowest emotional and physical 
aspect, vitality, and mental health component summary 
scores.
Most studies on HRQL and hypertension do not refer to 
patients with severe hypertension or complications but are 
restricted to patients with moderate or mild hypertension. 
Severe or complicated hypertension is defined as a diastolic 
blood pressure > 110 mm Hg for patients regardless of 
treatment status, with clinically evident target-organ damage 
(e.g., acute myocardial infarction, stroke, retinopathy) or 
other associated pathologies (e.g., diabetes, heart failure, 
renal diseases). 
The present study is aimed at assessing the influence of 
blood pressure control on the HRQL of hypertensive patients 
with and without complications.
MATERIALS AND METHODS
Seventy-seven  hypertensive  patients  seen  at  an 
ambulatory service of the General Hospital of São Paulo, 
Brazil were selected (71% women, 58% white, 60% with 
elementary school level, 54 ± 8 years) and enrolled in a 
12-month special care program for hypertensive patients 
(phase 1). After the special program was completed, the 
patients were called back three years later for the second 
phase of the study. The criteria for patients to be enrolled 
in the special care program included: a male or female 
adult between 18 to 60 years old, primary hypertension, a 
body mass index lower than 40 kg/m2, and must have been 
attending the special care program for hypertensive patients 
for six months. The hypertensive patients were classified 
into two groups: “with complications” and “without 
complications”.
Group 1. Hypertensive patients without complications
The following criteria were used to define patients 
without complications: systolic blood pressure > 140 mm 
Hg and/or diastolic blood pressure < 110 mm Hg and > 90 
mm Hg, either undergoing or not undergoing treatment, and 
no clinically evident target-organ damage . 
Group 2. Hypertensive patients with complications
Patients with complications met the following criteria: 
diastolic blood pressure ≥ 110 mm Hg either undergoing 
treatment or not, with clinically evident target-organ .
Study design
Hypertensive patients who were included in the study 
were assessed at two different points, in phase 1 (Special 
Care) and after three years in phase 2 (Usual Care).621
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Patients filled out an identification questionnaire and had 
their HRQL assessed using two questionnaires. In addition, 
anthropometric and blood pressure measurements were 
taken. All data were gathered on at the same appointment in 
both phases. The HRQL assessment was performed after the 
blood pressure measurements were taken.
Phase 1 – Special Care
In phase 1, patients attended a 12-month special care 
program for hypertensive patients. During this period, 
patients had to come to the hospital every two months 
to be seen by the same physician. The antihypertensive 
medications required by the patients were donated by the 
service itself. The patients also attended meetings held 
by the multidisciplinary team to talk about the disease, 
treatment, and life style. The patients also received active 
telephone calls from appropriately trained operators, as 
well as magazines with health-related information that were 
sent periodically by mail. In this phase, at the visit day, the 
patients were invited to take part in the present study and 
after providing written, informed consent, they followed the 
routine described.
Phase 2 – Usual Care
After the 12-month special care program (phase 1), the 
patients returned to usual care at the ambulatory clinic of the 
General Hospital or at another public institution. After three 
years, the patients were again evaluated in all aspects used 
in phase 1 to compare the maintenance of behavior identified 
in this phase. 
Usual care consisted of clinical visits every four months, 
oftentimes with a different physician. The medications 
were provided by the hospital drugstore, which had an 
approximately two-hour waiting time and potentially could 
have been out of medication. No group meetings with a 
multidisciplinary team were held, nor were any informative 
pamphlets distributed.
Patients enrolled in phase 1 were called by phone to 
schedule their appointment with the outpatient service. 
Age, sex, race, educational level, marital status, job 
status, smoking status, alcohol use, physical exercise, 
medical history, number of medications taken, and whether 
treatment was received at the General Hospital were 
determined by questionnaire (identification questionnaire) in 
both phases. Weight and height were measured to determine 
the body mass index (calculated as weight in kilograms 
divided by height in meters squared). 
Blood pressure measurement
A nurse measured the patient’s blood pressure five 
consecutive times with a one to two minute interval between 
each measurement using a validated automatic device 
(DIXTAL DX 2710)27 and an appropriate cuff size for the 
right arm. The five measurements were taken with the patient 
in a sitting position after a five minute rest. The average of 
the last three measurements was used for analysis. 
The “without complications”group received eight weeks 
of treatment with placebo followed by one of the following 
treatment regimens: a) hydrochlorothiazide (6.25 mg, two 
times a day) and atenolol (25 mg, two times a day) or b) 
losartan (25 mg two times a day) and amlodipine (2.5 
mg two times a day). If the blood pressure was unable 
to be controlled using these regimens, the doses were 
doubled or another antihypertensive was added. The “with 
complications” group did not undergo treatment with 
placebo. Patients in this group were randomized to receive 
drug regimens similar to the ones administered to the 
“without complications” group, considering the specificity 
of each condition. The addition of other antihypertensive 
agents in the “without complications”group, as well as 
the specific details of the treatment regimens for the “with 
complications” group, were decided according to established 
standards from the V Brazilian Guidelines on Arterial 
Hypertension.
Health-related quality-of-life (HRQL) assessment
Bulpitt and Fletcher’s Specific Questionnaire for HRQL 
assessment of hypertensive patients 
Bulpitt and Fletcher’s Questionnaire was designed for 
hypertensive patients undergoing treatment in the outpatient 
setting. It addresses the physical and psychological aspects 
of treatment, as well as the patient perception of the effect 
of antihypertensive treatment upon their lifestyle. It includes 
questions related to clinical conditions, adverse effects of the 
medications, as well as social, professional, emotional, and 
sexual subjects related to hypertension or its treatment. The 
questionnaire was translated into Portuguese and validated. 
The questions allowed for answers including yes, no, or open 
answers, which when analyzed provided a score ranging 
from 1 to 100. A higher score is correlated with a higher 
HRQL. 
General Questionnaire for HRQL assessment by the Medi-
cal Outcomes Study 36-item short-form Health Survey 
(SF-36)
The SF-36 is a general questionnaire for health 
assessment that has been applied in several studies and 
shown to be reproducible, valid, and responsive to changes 
in HRQL. It has been used for assessing several diseases 
by other investigators. For this study, it was translated into 
Portuguese and validated. The SF-36 is a multidimensional 622
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questionnaire, composed of 36 items, and it covers eight 
domains of health: functional capacity, physical aspects, 
bodily pain, overall health status, vitality, social aspects, 
emotional aspects, mental health, and one question that 
assesses the difference between the current health status and 
the status one year prior.
Each question in the SF-36 is given a score that is 
later translated to a scale from 0 to 100, in which zero 
corresponds to the worst health status and 100 to the 
best. Each domain is assessed separately in order to avoid 
not identifying real health-related problems as well as 
specific problems in each domain. Both HRQL assessment 
questionnaires were conducted via interview. 
Statistical analysis
Microsoft Excel was using for the processing, inference, 
and descriptive analyses of the data. Descriptive statistics 
was used to characterize the demographic and clinical data 
of patients, whereas the differences between groups were 
analyzed using the chi-square test and the Student’s t-test.
Scores obtained using the Bulpitt and Fletcher’s and SF-
36 questionnaires, as well as parametric data, were analyzed 
using the Kruskal-Wallis test. 
A p value less than 0.05 was considered significant.
RESULTS
Subjects
Seventy-seven hypertensive patients receiving outpatient 
treatment were enrolled in phase 1 (special care) and phase 
2 (usual care).
The assessment of hypertensive outpatients in the two 
phases of the study revealed the following results: a) both the 
systolic and diastolic blood pressure of showed a significant 
increase (p<0.05) between phase 1 (128±17/75±13 and 
128±15/ 83±11mm Hg for the patients with complications 
and patients without complications, respectively) and phase 
2 (143±18/ 84±11 and 144±21/93±11 mm Hg patients 
with complications and patients without complications, 
respectively); b) the patients with complications were 
significantly different from patients without complications 
with regards to the number of different drugs taken for 
antihypertensive treatment over the two phases (≥ 4 
medications compared to 1–3 drugs, p<0.05); c) for phase 
1, all hypertensive patients received treatment at the 
institution where the study was carried out, whereas over 
phase 2, 78% of the patients with complications, while only 
65% of the patients without complications remained under 
treatment at the same institution (p<0.05); d) there were no 
significant difference in the age, BMI, gender, race, marital 
status, education level, job, alcohol intake, physical exercise 
routine, smoking habits, or associated co-morbidities 
observed in the patients studied in both phases (Table 1).
Satisfactory blood pressure control (<140/90 mm Hg) 
was attained in 70% of the patients with complications 
and 78% of the patients without complications in phase 
1. In phase 2, there was a statistically significant decrease 
(p<0.05) in the proportion of patients who maintained 
satisfactory blood pressure control, as only 49% of the 
patients with complications and 50% of the patients without 
complications maintained blood pressure control (Figure 1).
HRQL assessment using Bulpitt and Fletcher’s Ques-
tionnaire 
The HRQL scores from the Bulpitt and Fletcher Specific 
Questionnaire for hypertensive patients were close to the 
maximum score of 100, showing that the HRQL of the 
patients studied was quite good. There was no statistically 
significant difference between the HRQL scores of patients 
with controlled blood pressure and those with uncontrolled 
blood pressure (Table 2). However, when comparing 
hypertensive patients with and without complicationsin 
phase 2, hypertensive patients without complications had 
HRQL scores (96.21) significantly higher than hypertensive 
patients with complications (94.98; p<0.05; Figure 1).
HRQL assessment using SF-36
The scores obtained from the eight domains of the SF-36 
demonstrated that the functional capacity and overall health 
status domains had the highest HRQL scores, whereas the 
vitality and mental health domains had the worst scores in 
both patients with and without complications, regardless of 
blood pressure control. 
The SF-36 HRQL assessment also revealed that 
Figure 1 - Blood pressure control in hypertensive patients with and without 
complications, according to phase of treatment.623
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hypertensive patients without complications had a HRQL 
score significantly higher (p<0.05) than patients with 
complications in the functional capacity (80.88 ± 16.83 vs. 
75.00 ± 20.68), bodily pain (72.00 ± 22.0 vs. 59.73 ± 20.68), 
and vitality (56.25 ± 16.67 vs. 47.57 ± 17.50) domains. The 
hypertensive patients with complications had a lower HRQL 
score in phase 1 than in phase 2 for the bodily pain (61.08 ± 
24.24 vs. 59.73 ± 20.68), vitality (62.57 ± 23.94 vs. 47.57 ± 
Table 1 - Age, gender, race, school level, marital status, job, body mass index (BMI), life habits, blood pressure, and number 
of medications taken of hypertensive patients with and without complications 
Characteristics Hipertensives
Complicated (n=37) Non-complicated (n=40)
Phase 1 Phase 2 Phase 1 Phase 2
Age (years) mean ± standard deviation 53 ± 8 56 ± 8 51 ± 9 55 ± 9
BMI (kg/m2) 32 ± 4 32 ± 4 29 ± 4 29 ± 4
Systolic BP (mmHg) 128 ± 17 143 ± 18* 128 ± 15 144 ± 21*
Diastolic BP (mmHg) 75 ± 13 84 ± 11* 83 ± 11 93 ± 11*
Gender n (%)
Female
Male
20 (54)
17 (46)
20 (54)
17 (46)
35 (87)
5 (12)
35 (87)
5 (12)
Race n (%)
White
Non-white
22 (59)
15 (41)
22 (59)
15 (41)
23 (57)
17 (43)
23 (57)
17 (43)
Marital status n (%)
Married
Non-married
23 (62)
14 (38)
23 (62)
14 (38)
28 (70)
12 (30)
28 (70)
12 (30)
School level n (%)
Illiterate/ Read-write
Elementary
Middle
University
6 (16)
22 (60)
9 (24)
0 (0)
6 (16)
22 (60)
9 (24)
0 (0)
6 (15)
24 (60)
8 (20)
2 (5)
6 (15)
24 (60)
8 (20)
2 (5)
Job n (%)
Non-specialized manual
Specialized manual
Not manual
Unemployed/ retired
18 (49)
11 (30)
2 (5)
6 (16)
18 (49)
11 (30)
2 (5)
6 (16)
27 (67.5)
7 (17.5)
4 (10)
2 (5)
27 (67.5)
7 (17.5)
4 (10)
2 (5)
Alcohol intake n (%)
Never
Quit
Often
27 (73)
7 (19)
3 (8)
27 (73)
7 (19)
3 (8)
30 (75)
5 (12.5)
5 (12.5)
30 (75)
5 (12.5)
5 (12.5)
Physical exercise routine n (%)
Never
Quit
Often
18 (49)
7 (19)
12 (32)
17 (46)
8 (22)
12 (32)
18 (45)
13 (33)
9 (22)
15 (38)
14 (35)
11 (27)
Smoking n (%)
Never
Quit
Often
18 (49)
16 (43)
3 (8)
18 (49)
16 (43)
3 (8)
23 (58)
11 (27)
6 (15)
23 (58)
11 (27)
6 (15)
Mellitus Diabetes n (%) 12 (32) 12 (32) - -
Acute Myocardial Infarction n (%) 2 (5) 4 (11) - -
Stroke n (%) 7 (19) 7 (19) - -
Renal disease n (%) 4 (11) 4 (11) - -
Nº of medications n (%)
1 to 3 16 (43) 15 (41) 34 (85)** 35 (88)**
≥ 4 21 (57) 22 (59) 6 (15)** 5 (12)**
Treated at the General Hospital n (%) 37 (100) 29 (78)* 40 (100) 26 (65)*
*p<0.05, phase 1 vs. phase 2; *p<0.05, complicated vs. non-complicated; BP=blood pressure
Table 2. Health-related quality of life scores obtained using 
Bulpitt and Fletcher’s Specific Questionnaire for Hyperten-
sive patients of the two treatment groups across both phases 
of this study.
Phase Controlled (n=38) Uncontrolled (n=39)
Phase 1 95.41±2.86 95.68±2.53
Phase 2 95.56±2.56 95.68±2.44624
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17.50), and mental health (64.65 ± 24.32 vs. 59.78 ± 17.51) 
domains. A statistically significant decrease in the vitality 
component summary score was observed between phase 1 
and phase 2 (58.03 ± 23.41 vs. 51.45 ± 15.51). However, a 
significant increase was observed from phase 1 to phase 2 
in the emotional aspect component summary score (56.14 ± 
43.91 vs. 72.81± 39.87) (Table 3).
DISCUSSION
The HRQL scores obtained using Bulpitt and Fletcher’s 
Specific Questionnaire for hypertensive patients showed no 
change in the HRQL between the two phases of the study. 
Overall, the HRQL scores were very high in both phases, 
suggesting that the antihypertensive treatments had few 
or no adverse effects on the patient quality of life. These 
results are similar to those found in other studies28-30 and 
they are likely due to the minimal side effects of modern 
antihypertensives. We also observed that patients without 
complications exhibited a significant improvement in quality 
of life compared to complicated hypertensive patients, even 
after phase 1. 
Another important finding was that the Bulpitt and 
Fletcher’s Questionnaire HRQL scores remained high 
regardless of blood pressure control. Even three years after 
the special care phase, when hypertension control had 
decreased significantly, the HRQL scores remained above 
90 out of a possible 100. This finding may be explained by 
the minimal impact of hypertension on quality of life, as it 
is an asymptomatic disease that only presents with long-
term complications. To illustrate this aspect of the disease, a 
study conducted in eight different countries measured quality 
of life in several chronic diseases. Hypertensive patients 
showed the best HRQL indices, which were close to those 
obtained by the control group, when compared with other 
diseases such as arthritis, pulmonary diseases, diabetes, 
congestive heart failure, and heart ischemic disease.30
The twelve-month special care program used in 
phase 1, which involved multidisciplinary activities, 
individualized and personalized assistance, easy access to 
pharmacological treatment, frequent meetings, and active 
telephone calls, undoubtedly contributed to the rate of 
successful hypertension control achieved. However, this 
situation was not sustainable after the special care program 
was terminated. Three years after phase 1, blood pressure 
control decreased significantly in both “with complications” 
(70% to 49%) and “without complications” patients (78% 
to 50%). However, during this period, none of the patients 
without complications studied had their condition worsen 
to the complicated status, and the blood pressure control 
Table 3 - Health-related quality of life scores by SF-36 dimensions.
Dimensions Hypertensive Patients
Complicated (n=37) Non- Complicated (n=40) Controlled (n=38) Uncontrolled (n=39)
Physical functioning
   Phase 1
   Phase 2
76.35 ± 21.23
75.00 ± 20.68
75.00 ± 20.25
80.88 ± 16.83*
78.29±20.67
80.53±17.27
73.08±20.48
75.64±20.27
Role-physical
   Phase 1
   Phase 2
70.27 ± 38.11
62.84 ± 38.02
73.75 ± 35.33
76.25 ± 36.23
76.32±36.74
67.76±37.18
67.95±36.25
71.79±38.12
Pain
   Phase 1
   Phase 2
61.08 ± 24.24
59.73 ± 20.68**
62.50 ± 22.50
72.00 ± 22.10*
59.74±19.10
64.74±24.36
63.85±26.72
67.44±27.50
General health perception
   Phase 1
   Phase 2 72.84 ± 15.75
70.95 ± 17.27
72.00 ± 19.96
73.50 ± 20.58
68.82±18.94
70.39±18.25
75.90±16.42
74.10±19.73
Vitality
   Phase 1
   Phase 2
62.57 ± 23.94
47,57 ± 17.50**
57.13 ± 23.86
56.25 ± 16.67*
58.03±23.41
51.45±15.51**
61.41±24.55
52.69±19.46**
Social functioning
   Phase 1
   Phase 2
73.24 ± 24.67
66.28 ± 22.80
64.25 ± 29.31
68.50 ± 20.58
65.33±29.43
66.18±22.15
71.73±25.20
68.65±21.18
Role-emotional
   Phase 1
   Phase 2
62.16 ± 44.56
76.58 ± 32.27
56.67 ± 43.49
65.83 ± 41.68
56.14±43.91
72.81**
62.39±44.05
69.23±38.53
Mental Health
   Phase 1
   Phase 2
64.65 ± 24.32
59.78 ± 17.51**
54.00 ± 26.49
58.80 ± 19.75
58.63±26.83
59.26±18.60
59.59±25.23
59.28±18.83
*p<0.05, complicated vs. non-complicated
**p<0.05, phase 1 vs. phase 2625
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level remained similar or better than those observed in other 
countries.10-16 A major reason for inadequate control of 
hypertension is poor adherence to treatment. Many reasons 
exist for non-adherence to medical regimens, including 
adverse drug effects, poorly provided instructions, a poor 
provider-patient relationship, poor patient memory, patient 
disagreement with the need for treatment, or patient inability 
to pay for treatments.31
The relationship between quality of life and compliance 
is complex and merits careful study. Monitoring quality 
of life may be one of the best ways to improve treatment 
adherence. Therefore, when developing an approach for 
hypertension treatment, physicians should consider the 
impact of different antihypertensives on the overall well 
being of the patient. Consideration of quality of life issues, 
along with side effects and contraindications, should 
determine the choice of medication administered.32
The SF-36-based HRQL assessment revealed that there 
were differences between the two phases of the study as well 
as between patients with and without complications. Three 
of the eight domains analyzed in the “with complications” 
group exhibited a decrease in the HRQL between phase 
1 and phase 2: bodily pain, vitality, and mental health. As 
hypertension is often asymptomatic, it is not surprising that 
the functional capacity and physical aspects domains would 
remain unchanged. However, according to Bulpitt et al.,24 
the awareness of having the disease and the association of 
hypertension with death can be responsible for changing 
quality of life. Furthermore, a change in one HRQL 
dimension can impact other dimensions. Indeed, the mental 
health domain could be responsible for changing the bodily 
pain and vitality domains due to somatization caused by the 
awareness of having the disease. This phenomenon has been 
demonstrated in a study carried out in Japan, which observed 
that changes in the mental health domain were responsible 
for worsening other HRQL domains assessed by the SF-36.
In the hypertensive group without complications, there 
was no change in scores in any HRQL domain in the SF-36 
during either phase. This finding suggests that quality of 
life is not related to blood pressure level, but rather to how 
severe the co-morbidities caused by hypertension are. A 
study to assess the impact of co-morbidities in hypertensive 
patients has demonstrated that patients with associated 
co-morbidities show significant reduction in the quality of 
life when compared with those who do not suffer from co-
morbidities. 29
Although the HRQL was not measured at baseline, the 
scores found for the different SF-36 domains were similar 
and even superior29 to those observed in other studies of 
hypertensive patients with and without complications.33,34 
These scores tended to be lower than those found for 
normotensives,35 suggesting that hypertension really causes 
several changes in the life of a patient. The SF-36 assesses 
hypertensive patients more broadly and, as such, was more 
sensitive than Bulpitt and Fletcher’s Questionnaire to detect 
changes in quality of life.
Working directly with hypertensive patients through 
the special care program demonstrated that blood pressure 
can be reduced to a satisfactory level without changing the 
HRQL. However, these reductions were not sustainable, 
regardless of the inherent characteristics of the population 
studied. It is important to point out that improving access 
to pharmacological treatments is a key factor our country 
needs to improve upon in order to ensure better treatment 
compliance and effective blood pressure control. A study 
conducted in Hungary also assessed the effectiveness 
of a special care program called “Manage it well” for 
hypertensive patients. The outcomes of this study showed 
that strategies similar to those used in the present study 
significantly increased treatment success, decreased the 
in-office blood pressure measurements, and significantly 
increased blood pressure control (from 2.9% at baseline to 
40.9% after a six-month intervention).36 There is no doubt 
that the best levels of hypertension control are observed 
in randomized, prospective clinical trials that assess the 
efficiency of antihypertensive drugs. However, it is evident 
that each of these studies does not represent the treatment 
reality for hypertensive patients.37-40
Hypertension control is clearly related to treatment 
compliance, which is one of the greatest challenges faced by 
physicians today. Several factors can influence compliance 
with antihypertensive treatment. These factors can be related 
to the patient (e.g., gender, age, race, marital status, school 
level, and social economical level), to the disease (e.g., how 
chronic it is, absence of symptoms, and late consequences), 
to health beliefs, life circumstances and cultural habits (e.g., 
perception and severity of the problem, unawareness of the 
disease, experience with the disease in a family context, and 
self-esteem), to the treatment (e.g., cost, side effects from 
drugs, complex treatment programs), to the institution (e.g., 
health policy, health service utilization, waiting time vs. care 
delivered time), and to the patient-health team relationship.22
The high HRQL scores attained in phase 1 in the 
present study are likely due to the special care program 
and more aggressive treatment over twelve months, but 
this practice is not usual in public health services in 
Brazil. Less aggressive treatments and physician apathy 
towards high blood pressure1,9 have been identified 
as being responsible for the lack of blood pressure 
control.21-22 In the present study, roughly 60% of the 
patients with complications were required to take more 
than four antihypertensive medications, whereas only 626
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15% of the patients without complications needed to 
take the same number. Antihypertensive treatments aim 
to reduce cardiovascular morbidity and mortality. Thus, 
pharmacological treatments should not only seek to lower 
blood pressure, but also decrease the number of fatal and 
non-fatal cardiovascular events. Blood pressure should be 
reduced to lower than 140/90 mm Hg, taking into account 
individual characteristics, presence of co-morbidities, and 
patient quality of life.1 Often multiple medications are 
required to achieve therapeutic goals. It has been observed 
that, in general, at least three therapeutic classes are needed 
to attain an acceptable blood pressure, which is often beyond 
recommendations.41 Excellent well-designed clinical trials 
have restated the importance of medication for hypertension 
treatment.38,42
In conclusion, the present study showed that a special 
care program for hypertensive patients reduced blood 
pressure and significantly increased blood pressure control 
without greatly affecting the HRQL. It is important to note 
that hypertensive patients with higher distress levels, more 
co-morbidities, and complications from their disease have a 
different quality of life and degree of blood pressure control 
compared to hypertensive patients without complications. 
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